< Back to previous page
Researcher
Steven Simoens
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today
Projects
1 - 10 of 22
- How to create sustainable market access to advanced therapies?From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Health Economic Evaluations of Preventive Policies in Flanders (HELPPFL)From22 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Exploring the market access of advanced therapy medicinal products (ATMPs)From17 Oct 2022 → 9 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Exploring the market environment of biologics including biosimilar medicinesFrom20 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market SustainabilityFrom16 Oct 2019 → 13 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- A Belgian policy framework for best-value biological medicinesFrom3 Sep 2019 → 18 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2019 → 23 Oct 2020Funding: FWO Strategic Basic Research Grant
Publications
11 - 20 of 428
- Public health impact and return on investment of Belgium’s pediatric immunization program(2023)
Authors: Jeroen Luyten, Steven Simoens, Marc Van Ranst
- Population health management in Belgium: a call-to-action and case study(2023)
Authors: Bert Vaes, Sabina De Geest, Steven Simoens
- Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults =60 Years in Belgium(2023)
Authors: Steven Simoens
- Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends(2023)
Authors: Elif Car, Arnold Vulto, Isabelle Huys, Steven Simoens
- Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies(2023)
Authors: Steven Simoens
Pages: 393 - 424 - An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain(2023)
Authors: Arnold Vulto, Isabelle Huys, Steven Simoens
- Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases.(2023)
Authors: Steven Simoens
Pages: 2239557 - The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire.(2023)
Authors: Steven Simoens, Isabelle Huys
Pages: 2217543 - Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis(2022)
Authors: Teresa Barcina Lacosta, Arnold Vulto, Isabelle Huys, Steven Simoens
- Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study(2022)
Authors: Khadidja Abdallah, Kathleen Claes, Isabelle Huys, Steven Simoens